证券代码：605388 证券简称：均瑶健康 公告编号：2023-045 湖北均瑶大健康饮品股份有限公司 第五届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）第五届董事会第 二次会议于 2023 年 8 月 24 日上午在公司会议室以现场结合通讯会议方式召开， 本次会议通知于 2023 年 8 月 14 日以电子邮件形式送达公司全体董事。本次会议 由公司董事长王均豪先生主持。会议应出席董事 9 人，实际出席董事 9 人，公司 监事和高级管理人员列席了本次会议。本次会议的召开符合《公司法》和《公司 章程》等有关规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2023 年半年度报告及摘要的议案》 董事会审议并通过《湖北均瑶大健康饮品股份有限公司2023年半年度报告》 及《湖北均瑶大健康饮品股份有限公司 2023 年半年度报告摘要》。 具体内容详见同日披露于上海证券交易所网站（www.sse.com.cn）的《湖北 均瑶大健 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2023-048 湖北均瑶大健康饮品股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的专 项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所股票上市规则》、《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求》和《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》等有关规定，湖北均瑶大健康饮品股份有限公司 （以下简称"公司"或"均瑶健康"）董事会对 2023 年半年度募集资金存放与 使用情况专项报告说明如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准湖北均瑶大健康饮品股份有限公司 首次公开发行股票的批复》（证监许可[2020]1568 号）核准，公司向社会公众 投资者发行人民币普通股（A 股）70,000,000.00 股，发行价格为每股 13.43 元， 募集资金总额 940,100,000.00 元，扣除各项发行费用后，募集资金净额为人民 币 88 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2023-047 湖北均瑶大健康饮品股份有限公司 2023 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十二 号——酒制造》的相关规定，现将湖北均瑶大健康饮品股份有限公司（以下简称 "公司"）2023 年半年度主要经营数据（未经审计）公告如下： 注：为更清晰的反应公司整体经营活动现金流量特征，根据企业会计准则及 相关规定，并参考部分同类公司的做法，公司 2022 年四季度将部分业务改为净 额法编报，同步修改 2022 年前三季度可比报表营业收入，故本期同时调整本公 告 2022 年 1-6 月相应数据，下同。 2、按区域分类情况： 单位：元 单位：元 产品类别 2023 年 1-6 月主 营业务收入 2022 年 1-6 月主 营业务收入 变动比例 （%） 乳酸菌饮品 342,887,083.50 325,129,607.24 5.46 益生菌饮品 12,374,651.06 1 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2023-050 湖北均瑶大健康饮品股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 09 月 14 日（星期四）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 投资者可于 2023 年 09 月 07 日(星期四)至 09 月 13 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2023 年 08 月 25 日发布《公司 2023 年半年度报告》，为便于广大投资者更全面深入地了解 公司 2023 年半年 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2023-044 湖北均瑶大健康饮品股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发股份；股票认购方式为网下，上市股数为 289,141,717 股。 本次股票上市流通总数为 289,141,717 股。 本次股票上市流通日期为 2023 年 8 月 18 日。 一、本次限售股上市类型 湖北均瑶大健康饮品股份有限公司（以下简称"均瑶健康"或"公司"）经中 国证券监督管理委员会（以下简称"中国证监会"）《关于核准湖北均瑶大健康饮 品股份有限公司首次公开发行股票的批复》（证监许可[2020]1568 号）核准，首次 公开发行人民币普通股（A 股）股票 70,000,000 股，并于 2020 年 8 月 18 日在上海 证券交易所上市。首次公开发行完成后，公司总股本增加至 430,000,000 股，其中， 有限售条件流通股股份数量为 360,000,000 股，无限售条件流通股股份数量 ...

国泰君安证券股份有限公司、爱建证券有限责任公司 关于湖北均瑶大健康饮品股份有限公司 首次公开发行股票部分限售股解禁上市流通的核查意见 国泰君安证券股份有限公司、爱建证券有限责任公司(以下简称"联合保荐机构") 作为湖北均瑶大健康饮品股份有限公司(以下简称"均瑶健康"或"公司")首次公开发 行股票并上市的持续督导联合保荐机构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所股票上市规则》以及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关规定，对均瑶健康首次公开发行股票部分限售股份解禁 上市流通事项进行了核查，核查情况及核查意见如下： 一、本次限售股上市类型 均瑶健康经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准湖 北均瑶大健康饮品股份有限公司首次公开发行股票的批复》（证监许可[2020]1568 号）核准，首次公开发行人民币普通股（A 股）股票 70,000,000 股，并于 2020 年 8 月 18 日在上海证券交易所上市。首次公开发行完成后，公司总股本增加至 430,000,000 股，其中，有限售条件流通股股份数量为 360,000,000 股，无限售条件 流 ...

关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 31 日（星期三）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 证券代码：605388 证券简称：均瑶健康 公告编号：2023-034 湖北均瑶大健康饮品股份有限公司 投资者可于 2023 年 5 月 30 日(星期二)16:00 前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日发布公司 2022 年度报告，于 2023 年 4 月 26 日发布公司 2023 年第一季度 报告，为便于广 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥445,358,945.57, representing a year-on-year increase of 102.84%[5] - Net profit attributable to shareholders was ¥23,916,582.84, reflecting a growth of 30.88% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 35.69%, amounting to ¥18,560,195.20[5] - Basic and diluted earnings per share both rose by 50.00%, reaching ¥0.06 per share[5] - Operating profit for Q1 2023 was ¥33,559,160.01, up 39.5% from ¥24,055,336.49 in the same period last year[23] - Net profit for Q1 2023 was ¥25,089,016.23, representing a 40.3% increase from ¥17,877,917.67 in Q1 2022[24] - The company reported a total comprehensive income of ¥25,089,016.23 for Q1 2023, compared to ¥17,877,917.67 in Q1 2022, indicating a growth of 40.3%[24] Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥92,212,326.92, indicating a significant cash outflow[5] - As of March 31, 2023, the company's cash and cash equivalents decreased to ¥350,039,060.41 from ¥679,573,145.89 as of December 31, 2022, representing a decline of approximately 48.7%[18] - The company's total current assets decreased to ¥1,074,184,524.79 from ¥1,275,853,913.67, a reduction of about 15.7%[19] - The company's inventory decreased to ¥165,470,212.87 from ¥172,441,648.85, reflecting a decline of approximately 4.0%[19] - The company's total liability was ¥336,105,983.23 as of March 31, 2023, down from ¥463,581,613.79, indicating a decrease of approximately 27.4%[20] - The company's non-current assets increased to ¥1,198,002,162.87 from ¥1,113,428,881.49, showing an increase of about 7.6%[19] Market and Growth Strategies - The growth in revenue is attributed to increased consumer demand due to economic recovery, proprietary technology, new products, and online channels[9] - The company has implemented cost reduction and efficiency improvement measures, contributing to the increase in profitability[9] - The company reported significant growth in key operating metrics for the first quarter of 2023, benefiting from increased consumer demand and reduced raw material costs[14] - The lactobacillus business has resumed growth, with product upgrades enhancing core competitiveness, including the introduction of patented health function strains[14] - The company has signed a strategic cooperation agreement with Jiangnan University to develop new strains related to gastrointestinal health, aiming to enrich its product matrix[14] - The company plans to expand its distribution channels to cover town-level markets, enhancing its market presence in lower-tier cities[14] - The restructuring of Junyao Runying Biotechnology (Shanghai) Co., Ltd. has been successfully completed, opening up a second growth curve for probiotics[15] - The company aims to establish a differentiated segment in the lactobacillus market focused on "gut health," leveraging technological patents to maintain industry leadership[14] - The company is focused on enhancing its brand loyalty and meeting consumer needs through innovative product offerings[14] - The overall market sentiment is improving, with a recovery in consumer confidence contributing to the company's positive performance outlook[14] - The company achieved significant breakthroughs in product development, launching new products that received positive market feedback and securing major contracts, laying a solid foundation for annual revenue targets[16] - The company aims to enhance its probiotic brand matrix and expand market influence through improved product offerings and channel strategies[16] - The company plans to leverage its partnership with Junyao Runying to maximize synergy across the entire supply chain of probiotics, enhancing overall operational efficiency[16] Costs and Expenses - Total operating costs for Q1 2023 were ¥419,222,497.70, an increase of 109.3% from ¥199,906,434.66 in Q1 2022[22] - Research and development expenses for Q1 2023 were ¥3,876,444.20, a decrease of 24.2% compared to ¥5,113,114.70 in Q1 2022[22] - The company has implemented cost control measures, optimizing expense allocation to improve efficiency[14] - The company has adjusted the ex-factory prices of some products due to the recent upgrades and inflationary pressures on raw materials[14]

Financial Performance - In 2022, the company achieved a net profit attributable to all shareholders of RMB 76,631,268.40, with a total distributable profit of RMB 418,893,647.68 at the end of the reporting period[5]. - The company's operating revenue for 2022 was CNY 986,104,247.74, representing a year-on-year increase of 7.94% compared to CNY 913,598,918.70 in 2021[26]. - The net profit attributable to shareholders for 2022 was CNY 76,631,268.40, a decrease of 47.87% from CNY 146,987,705.81 in 2021[26]. - The basic earnings per share for 2022 was CNY 0.18, down 47.06% from CNY 0.34 in 2021[28]. - The cash flow from operating activities for 2022 was CNY 179,878,265.00, a significant decrease compared to CNY 81,721,356.48 in 2021, reflecting a decline of 258.10%[26]. - The company's net assets attributable to shareholders at the end of 2022 were CNY 1,921,191,424.25, a slight decrease of 0.93% from CNY 1,930,840,672.63 at the end of 2021[26]. - The weighted average return on equity for 2022 was 3.99%, down from 7.33% in 2021, a decrease of 3.34 percentage points[28]. - The company reported a significant increase in costs due to higher raw material prices and increased investment in probiotic products, impacting net profit[29]. - The fourth quarter of 2022 saw a net profit of CNY -2,279,853.50, contrasting with profits in the previous three quarters[31]. Dividend Policy - The proposed cash dividend for 2022 is RMB 1.00 per 10 shares (including tax), amounting to a total of RMB 43,000,000 (including tax), resulting in a cash dividend payout ratio of 56.11%[5]. - The company maintains a stable dividend distribution policy to protect investors' legitimate rights and interests[5]. Market and Product Development - The company plans to continue focusing on product development and market expansion to improve future performance[29]. - The company's probiotic business achieved sales revenue exceeding 80 million yuan, representing a year-on-year growth of 43%[41]. - The new product "Post-meal Light Body" became the second product after "Taste Power 330" to exceed 100 million yuan in sales, indicating strong growth potential[41]. - The company launched 72 new SKUs in the probiotic product line, transitioning from a steady pace to a "small steps, quick runs" approach in product innovation[42]. - The number of new retail channels, including urban CVS and vending machines, increased by 11,000 by the end of 2022, enhancing market coverage[41]. - The company's e-commerce sales grew by 46%, with 18 official stores established across various platforms including Tmall and JD[42]. Strategic Initiatives - The company signed strategic cooperation agreements with universities to enhance its innovation capabilities in the health industry[42]. - The company established a "Probiotics & Postbiotics Health Functional Food Innovation Center" in collaboration with Northeast Agricultural University and Shanghai University of Science and Technology to promote sustainable development in the health food industry[43]. - The acquisition of Junyao Runying, a leading domestic probiotics manufacturer, added over 30 local probiotic strains and a resource library of more than 4,000 proprietary strains, enhancing the company's industry position[43]. - The company aims to develop Junyao Runying into the largest and most competitive probiotics raw material leader in China within three years, leveraging its core capabilities in the Shanghai market[44]. Operational Efficiency - The company operates its own factories in Yichang, Hubei, and Quzhou, Zhejiang, but faces capacity constraints that limit production during peak seasons[52]. - The company utilizes a contract manufacturing model to supplement its production capacity, ensuring a steady supply of products to meet market demand[52]. - The company has established a comprehensive sales network focused on second- and third-tier cities, developing a single distributor per region to enhance marketing efficiency[53]. - The company has invested significantly in R&D to improve production processes and ensure the stability and advancement of its technology[55]. - The company has formed an integrated supply chain for probiotics, covering raw material production to end-product manufacturing, enhancing its competitive edge in the market[55]. Risk Management - There are no significant risks that materially affect the company's production and operations during the reporting period[9]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company acknowledges risks from intensified market competition and fluctuating raw material prices, particularly in the probiotic beverage sector[133]. - The company has established a comprehensive quality control system covering procurement, production, storage, distribution, and sales to address food safety risks[134]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present at the board meeting[8]. - The company has committed to strict compliance with the regulatory requirements and will submit a rectification report within the specified timeframe[157]. - The company has implemented a robust internal control system, with no significant deficiencies reported during the evaluation period[183]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, linking operational indicators to annual business goals[182]. Social Responsibility - The company has committed to social responsibility by donating 60 million yuan worth of probiotic drinks to support disaster relief efforts[189]. - The company has established a long-term poverty alleviation mechanism through employment and development initiatives, benefiting local communities[190].

Financial Performance - The company's revenue for Q3 2022 reached ¥303,971,479.03, representing a year-on-year increase of 35.99%[5] - Net profit attributable to shareholders for Q3 2022 was ¥33,489,385.99, a significant increase of 71.55% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥28,138,724.03, up 82.06% year-on-year[5] - Year-to-date revenue as of Q3 2022 totaled ¥844,841,561.52, reflecting a 20.62% increase compared to the same period last year[5] - Year-to-date net profit attributable to shareholders decreased by 45.21% to ¥78,911,121.91 due to increased costs and pandemic-related disruptions[5][10] - The basic earnings per share for Q3 2022 was ¥0.08, a decrease of 45.45% year-to-date[6][10] - The net profit for Q3 2022 was CNY 78,433,591.54, a decrease of 45% compared to CNY 142,829,123.17 in Q3 2021[26] - The total profit for Q3 2022 was CNY 98,292,856.77, down 48.9% from CNY 192,694,704.70 in the same period last year[26] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.18, compared to CNY 0.33 in Q3 2021, reflecting a decline of 45.5%[28] Cash Flow and Assets - The company reported a significant cash flow deficit from operating activities of -¥297,731,355.85 for the year-to-date period[6] - The company's cash and cash equivalents decreased to CNY 586,225,646.10 as of September 30, 2022, down 45.6% from CNY 1,077,382,405.31 at the end of 2021[20] - Cash and cash equivalents at the end of Q3 2022 were CNY 571,768,192.77, down from CNY 1,200,136,754.39 at the end of Q3 2021[31] - The total assets as of the end of Q3 2022 were ¥2,151,818,462.32, down 6.30% from the end of the previous year[6] - The total assets of the company as of September 30, 2022, were CNY 2,151,818,462.32, a decrease of 6.3% from CNY 2,296,495,401.64 at the end of 2021[22] - The total liabilities decreased to CNY 221,152,428.47 as of September 30, 2022, down 36.7% from CNY 349,662,959.33 at the end of 2021[22] Operational Challenges and Strategies - The company attributed the decline in net profit to increased R&D investments and rising raw material costs, along with pandemic-related operational challenges[10] - The company has implemented cost reduction and efficiency enhancement strategies to counteract rising raw material prices, optimizing its cost structure[14] - The company is focusing on new product development and channel expansion to drive future growth[10] - The company aims to enhance digital capabilities to support operational visualization and precision marketing, focusing on integrating online and offline customer experiences[18] Product Development and Market Strategy - The "Weidongli" ambient yogurt beverage business achieved both quarter-on-quarter and year-on-year revenue growth in Q3 2022[14] - The functional probiotic product matrix has been enriched, establishing initial product barriers for long-term strategic implementation[14] - New probiotic products, including the "Qingyou" and "Changyin" series, have shown significant growth, with the "Xianmeijun" series launched in the second half of the year[15] - The company is focusing on a dual-channel strategy to expand its market presence among first and second-tier consumers and new retail channels[17] - The company aims to become a globally competitive enterprise in the probiotic industry through strategic partnerships and supply chain integration[16] Research and Development - Research and development expenses for the first three quarters of 2022 were CNY 13,705,502.95, significantly higher than CNY 5,910,809.38 in the same period of 2021, reflecting a growth of 132.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,488[12] - The largest shareholder, Shanghai Junyao Group, holds 32.66% of shares, with 140,451,430 shares pledged[12]